#ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in IL-2 as s/c every other day for 12 wks, followed by weekly for another 12 wks vs PBO. Efficacy & T-regs expansion were dose dependent. On to Phase 3 @RheumNow https://t.co/L0rYr5D1R1

• https://x.com/Yuz6Yusof/status/1983210295192375678/photo/1

CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f

• https://x.com/AkhilSoodMD/status/1983207128077873559/photo/1

Late Breaker: Phase 2 RCT of low dose IL2 in SLE Dose dependent response in SRI4 over 12 weeks & surprisingly high rates of LLDAS Too early to know if useful, but worth evaluating in a phase 3 #ACR25 @RheumNow Abstr#LB01 https://t.co/oPOLG82nwi

• https://x.com/EBRheum/status/1983206373065470152/photo/1

Late Breaker: Observational study of MEPO in EGPA 375 pts receiving MEPO had less ARF/CKD than 727 pts receiving standard of care Smallish event #'s & lots of p values... also, what about the vasculitis?!? #ACR25 @RheumNow AbstLB16 https://t.co/XwqNthfwPF

• https://x.com/EBRheum/status/1983200585374380336/photo/1
• https://x.com/EBRheum/status/1983200585374380336/photo/1

Semaglutide isn’t just for weight loss? In RA, users had 20–40% lower risk of synovitis, stiffness & swelling up to 1 year vs matched controls. GLP-1 agonists may offer anti-inflammatory benefit beyond metabolism. @RheumNow #ACR25 Abstract#2286

The CAR T engine doesn’t stop! LB04: Phase 1 bispecific CD19/BCMA CAR T in refractory autoimmune disease 🚗💥 ✅ Low AEs (mostly Gr 1–2 CRS, hematologic) 💪 Robust efficacy in lupus nephritis 🔄 Deep B-cell depletion → naïve B-cell repopulation @RheumNow #ACR25

Does specific ANCA subtype inform infectious risk? Retrospective review of 270 AAV patients revealed that about 1/3 pt developed severe infections... of these: - 64.1% MPO+ - 35.9% PR3+ Most infx during year 1 of tx No difference between CYC vs. RTX @RheumNow #ACR25 abst 2510

Simulation modeling by Patel et al helps generate probability of remission, relapse, and adverse events in newly dx AAV Projected risk by model were similar to observed rates in RCTs @RheumNow #ACR25 Abst 1764 https://t.co/xevkJ2Ih0M

• https://x.com/Dr_Brian_MD/status/1983189598806388769/photo/1
• https://x.com/Dr_Brian_MD/status/1983189598806388769/photo/1

#1724 MAIT cells central in RA pathogenesis. These innate-like T cells accumulate in synovial fluid, driving fibroblast activation, cytokine release & joint damage. Blocking MAIT activation or deleting MR1 reduces arthritis in mice- a potential new target in RA. @RheumNow #ACR25

The Power of Gamma Delta T Cell for Autoimmunity https://t.co/wIMu5r7b3D More on T Cell engagers , this time with gama delta T cell ( tiny but mighty ). Kate Roslin talks about advantages of this protocol. (No cytokines thus less toxicity). @Yuz6Yusof @RheumNow #ACR25

• The Power of Gamma Delta T Cell for Autoimmunity

#ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5

• The Power of Gamma Delta T Cell for Autoimmunity
• https://x.com/Yuz6Yusof/status/1983153161717330337/photo/1

#ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumomab in #SLE @RheumNow https://t.co/5JrLG41nsD https://t.co/KeY6AkHUNK

• Progressive BiTE in SLE 2
• https://x.com/Yuz6Yusof/status/1983150449952768008/photo/1